Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| NEGATIVE | AMBIG |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the effectiveness of buccal misoprostol and comparing this with vaginal route of the same drug.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Buccal Misoprostol | Active Comparator | Group one: 50 patients with first trimester missed abortion received buccal misoprostol |
|
| Vaginal Misoprostol | Active Comparator | Group two: 5 patients received vaginal misoprostol |
|
| Buccal and Vaginal Misoprostol | Active Comparator | 50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects. Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Misoprostol (given buccally) | Drug | 400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms) |
| Measure | Description | Time Frame |
|---|---|---|
| To compare the efficacy of buccal administration to the more commonly vaginal route for preoperative cervical and priming in patients with first trimester surgical abortion. (Buccal Vs. Vaginal Misoprostol in the First Trimester Missed Abortion.) | March 2007 to March 2008 |
| Measure | Description | Time Frame |
|---|---|---|
| The secondary objectives are to compare the side effects and acceptability by the subjects. | March 2007 to March 2008 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
history or evidence of disorders that represent contraindication to the use of misoprostol:
patient's refusal to participate in the study
patients with abnormal results of investigations
patients with previous operations on cervix like conisation, cauterization, previous dilatation and curettage
patients with complete abortion
patients with severe bleeding that required emergency surgical evacuation of the uterus
patients with partially dissolved tablets at the site of application in both groups
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| BASHAR Y F HANOOSHI, CABOG | IRAQI MEDICAL SPECIALIZATION/IRAQ | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Iraqi Medical Specialization | Risafa | Baghdad Governorate | 00964 | Iraq |
Not provided
| ID | Term |
|---|---|
| D000030 | Abortion, Missed |
| ID | Term |
|---|---|
| D000022 | Abortion, Spontaneous |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016595 | Misoprostol |
| ID | Term |
|---|---|
| D011459 | Prostaglandins E, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Misoprostol (given vaginally) | Drug | 400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms) |
|
|
| D005231 |
| Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |